COST-EFFECTIVENESS OF OBICETRAPIB OR FIXED-DOSE COMBINATION AS AN ADJUNCT TO MAXIMALLY TOLERATED STATINS
Author(s)
Jen Kammerer, BSc, MSc, PharmD1, Nancy Ortiz, PharmD2, Bhagyashree Oak, PhD3, Atish De, MS4, Katherine Park, MPH5, Nandini Hadkar, MS5, Nihar R Desai, MD, MPH6;
1New Amsterdam Pharma, Health Economics Outcomes Research, Adventura, FL, USA, 2New Amsterdam Pharma, Adventura, FL, USA, 3Trinity Lifesciences, Waltham, MA, USA, 4Trinity Life Sciences, New York, NY, USA, 5Trinity Life Sciences, Waltham, MA, USA, 6Yale University, New Haven, CT, USA
1New Amsterdam Pharma, Health Economics Outcomes Research, Adventura, FL, USA, 2New Amsterdam Pharma, Adventura, FL, USA, 3Trinity Lifesciences, Waltham, MA, USA, 4Trinity Life Sciences, New York, NY, USA, 5Trinity Life Sciences, Waltham, MA, USA, 6Yale University, New Haven, CT, USA
OBJECTIVES: Many patients receiving maximally tolerated statins fail to achieve guideline-directed low-density lipoprotein cholesterol (LDL-C) targets, leaving them at elevated risk for cardiovascular events. We sought to assess the cost-effectiveness of obicetrapib, an investigational, highly selective, novel cholesteryl ester transfer protein (CETP) inhibitor, or its fixed-dose combination (FDC) with ezetimibe, when used as adjuncts to maximally tolerated statins to reduce LDL-C and associated major adverse cardiovascular events (MACE) across primary and secondary prevention populations.
METHODS: A 3-state (above or at goal or death) Markov model was adapted to simulate outcomes for a 100,000-patient cohort on maximally tolerated stable-dose statins, over a lifetime horizon. Patients with atherosclerotic cardiovascular disease entered “Above Goal”, defined as LDL-C >70 mg/dL. Outcome rates were derived from Phase 3 BROADWAY and TANDEM (FDC) studies; MACE (stroke, myocardial infarction, revascularization, death) rates were estimated using BROADWAY outcomes for year one and published rates for subsequent years; TANDEM used published rates for all years. Direct medical and drug costs were incorporated, as were multiple obicetrapib pricing scenarios. Age-adjusted mortality was estimated using United States census tables. MACE rates, life years and quality-adjusted life years (QALYs) gained were calculated. One-way and probabilistic sensitivity analyses were conducted.
RESULTS: Compared to statins alone, add-on obicetrapib or FDC was cost-effective in both primary and secondary prevention populations at ICERs well under $150,000/QALY across multiple pricing scenarios. Adding obicetrapib increased treatment costs but reduced MACE events and costs; thus, significantly reduced medical costs.
CONCLUSIONS: Many patients fail to achieve LDL-C targets, leaving them at increased cardiovascular risk. Adding obicetrapib alone or in combination with ezetimibe is cost-effective and can enable goal attainment, event reduction, and QALY gains.
METHODS: A 3-state (above or at goal or death) Markov model was adapted to simulate outcomes for a 100,000-patient cohort on maximally tolerated stable-dose statins, over a lifetime horizon. Patients with atherosclerotic cardiovascular disease entered “Above Goal”, defined as LDL-C >70 mg/dL. Outcome rates were derived from Phase 3 BROADWAY and TANDEM (FDC) studies; MACE (stroke, myocardial infarction, revascularization, death) rates were estimated using BROADWAY outcomes for year one and published rates for subsequent years; TANDEM used published rates for all years. Direct medical and drug costs were incorporated, as were multiple obicetrapib pricing scenarios. Age-adjusted mortality was estimated using United States census tables. MACE rates, life years and quality-adjusted life years (QALYs) gained were calculated. One-way and probabilistic sensitivity analyses were conducted.
RESULTS: Compared to statins alone, add-on obicetrapib or FDC was cost-effective in both primary and secondary prevention populations at ICERs well under $150,000/QALY across multiple pricing scenarios. Adding obicetrapib increased treatment costs but reduced MACE events and costs; thus, significantly reduced medical costs.
CONCLUSIONS: Many patients fail to achieve LDL-C targets, leaving them at increased cardiovascular risk. Adding obicetrapib alone or in combination with ezetimibe is cost-effective and can enable goal attainment, event reduction, and QALY gains.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE318
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory)